Natera (NTRA) closed at $310.67 on November 6, 2026, down 14.6% from the previous close, on volume of 5,537,160 shares (30-day average 1,782,967).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | 6 Leg Put Combo with Ratio | 20-Nov-26320 : 350[1.5x] : 360[3.5x] : 380[1.5x] : 390 : 410[1.5x] P | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Goldman Sachs Reaffirms Their Hold Rating on Natera (NTRA)
TipRanks (Fri, 6-Nov 10:05 AM ET)
Market Chameleon (Fri, 6-Nov 4:55 AM ET)
Canaccord Genuity Remains a Buy on Natera (NTRA)
TipRanks (Fri, 6-Nov 9:53 AM ET)
Natera (NTRA) Gets a Buy from Piper Sandler
TipRanks (Fri, 6-Nov 9:37 AM ET)
Natera falls after Q3 earnings miss, CEO transition
Seeking Alpha News (Fri, 6-Nov 7:52 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Fri, 6-Nov 6:54 AM ET)
Barclays Sticks to Their Buy Rating for Natera (NTRA)
TipRanks (Fri, 6-Nov 4:07 AM ET)
Natera GAAP EPS of -$0.42 misses by $0.15, revenue of $794M beats by $86.5M
Seeking Alpha News (Thu, 5-Nov 4:27 PM ET)
Natera Announces Leadership Transition
Business Wire (Thu, 5-Nov 4:06 PM ET)
Natera Reports Third Quarter 2026 Financial Results
Business Wire (Thu, 5-Nov 4:05 PM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of November 6, 2026, NTRA stock price declined to $310.67 with 5,537,160 million shares trading.
NTRA has a beta of 1.46, meaning it tends to be more sensitive to market movements. NTRA has a correlation of 0.11 to the broad based SPY ETF.
NTRA has a market cap of $44.78 billion. This is considered a Large Cap stock.
Last quarter Natera reported $794 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $87 million and missed earnings estimates by -$.16.
In the last 3 years, NTRA traded as high as $437.41 and as low as $40.61.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
NTRA has outperformed the market in the last year with a return of +56.5%, while the SPY ETF gained +10.8%. In the last 3 month period, NTRA beat the market returning +17.1%, while SPY returned -4.1%. However, in the most recent 2 weeks NTRA has underperformed the stock market by returning -23.1%, while SPY returned -3.2%.
NTRA support price is $351.22 and resistance is $376.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.
